Amneal Pharmaceuticals, Inc. AMRX Inventory write-downs
Inventory write-downs at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InventoryWriteDown.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s inventory write-downs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s inventory write-downs?
- Amneal Pharmaceuticals, Inc. (AMRX) reported inventory write-downs of $13.35M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s inventory write-downs changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s inventory write-downs decreased by 43.6% year-over-year, from $23.67M to $13.35M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s inventory write-downs?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s inventory write-downs has grown at a 12.0% compound annual growth rate (CAGR), from $54.66M to $85.96M.
- What does inventory write-downs mean?
- This reflects the expense recognized when the carrying value of inventory exceeds its net realizable value due to obsolescence, damage, or market price declines. It serves as an indicator of inventory management efficiency and product lifecycle health.